Phase III multicenter, randomized, placebo-controlled, double-blinded clinical trial ofLenzilumab in hospitalized severe and critical adult COVID-19 patients at high risk of disease progression
Latest Information Update: 13 Aug 2020
At a glance
- Drugs Lenzilumab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Humanigen
- 13 Aug 2020 New trial record
- 10 Aug 2020 According to a Humanigen media release, the company announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.
- 10 Aug 2020 According to a Humanigen media release, the company is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.